文献速递腹部MR

肝硬化患者门静脉期肝脏强化:钆塞酸二钠与钆贝葡胺有何差异?

Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine?
PubMed 文献 · Abdom Radiol (NY) · 2020-01-01

回顾性纳入84例肝硬化患者,比较钆塞酸二钠与钆贝葡胺增强MRI门静脉期的肝脏实质及门静脉强化水平;钆塞酸二钠的肝脏相对强化、图像对比度及门静脉-肝对比差值均低于钆贝葡胺。

要点

  • 肝硬化患者门静脉期,钆塞酸二钠的肝脏相对强化低于钆贝葡胺。
  • 钆塞酸二钠的图像对比度及门静脉-肝对比差值均低于钆贝葡胺。
  • 两位阅片者测量肝脏相对强化的一致性ICC为0.94。

核心结论

  • 肝硬化患者门静脉期,钆塞酸二钠的肝实质强化及门静脉对比均低于钆贝葡胺。

研究设计与样本

  • 回顾性研究纳入84例肝硬化患者,平均年龄66±13岁,于2012至2018年间接受钆塞酸二钠和钆贝葡胺增强MRI。
  • 两位阅片者测量平扫及门静脉期肝实质、门静脉和腰大肌信号强度,计算相对强化、图像对比度及门静脉-肝对比差值。
  • 组内差异采用Wilcoxon符号秩和检验,阅片者间差异采用组内相关系数(ICC)评估。

诊断标准与关键数值

  • 门静脉期肝脏相对强化:阅片者1钆塞酸二钠42.4±44.6 vs 钆贝葡胺56.1±58.8(p=0.044);阅片者2钆塞酸二钠42.4±42.9 vs 钆贝葡胺57.7±60.5(p=0.027)。
  • 门静脉期图像对比度:阅片者1钆塞酸二钠0.27±0.11 vs 钆贝葡胺0.35±0.11(p<0.001);阅片者2钆塞酸二钠0.29±0.10 vs 钆贝葡胺0.37±0.07(p<0.001)。
  • 门静脉期门静脉-肝对比差值:阅片者1钆塞酸二钠0.89±0.39 vs 钆贝葡胺1.42±0.90(p<0.001);阅片者2钆塞酸二钠0.95±0.40 vs 钆贝葡胺1.28±0.37(p<0.001)。
  • 阅片者间ICC:相对强化0.94,图像对比度0.79,门静脉-肝对比差值0.69。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To compare the level of parenchymal and portal venous enhancement in the portal venous phase (PVP) in cirrhotic patients undergoing gadoxetate disodium- and gadobenate dimeglumine-enhanced MRI.

METHODS: In this retrospective study, 84 cirrhotic patients (mean age ± SD: 66 ± 13 years) who underwent contrast-enhanced MRI with both gadoxetate disodium and gadobenate dimeglumine between 2012 and 2018 were included. Two readers measured signal intensities of hepatic parenchyma, portal vein and psoas muscle on precontrast and PVP. Relative enhancement (RE), image contrast, and portal vein-to-liver contrast difference were calculated. Intraindividual differences were compared with the Wilcoxon signed rank-sum test and inter-reader differences with the intraclass correlation coefficient (ICC).

RESULTS: In PVP, gadoxetate disodium provided lower RE than gadobenate dimeglumine (Reader 1: 42.4 ± 44.6 vs. 56.1 ± 58.8, p = 0.044; Reader 2: 42.4 ± 42.9 vs. 57.7 ± 60.5, p = 0.027;), lower image contrast (Reader 1: 0.27 ± 0.11 vs. 0.35 ± 0.11, respectively; p < 0.001; Reader 2: 0.29 ± 0.10 vs. 0.37 ± 0.07, respectively; p < 0.001), and lower portal vein-to-liver contrast difference (Reader 1: 0.89 ± 0.39 vs. 1.42 ± 0.90, p < 0.001; Reader 2: 0.95 ± 0.40 vs. 1.28 ± 0.37, p < 0.001). ICC was 0.94, 0.79, and 0.69 for RE, image contrast, and portal vein-to-liver contrast difference, respectively.

CONCLUSION: In cirrhotic patients, gadoxetate disodium yielded lower enhancement of the hepatic parenchyma and lower contrast of the portal vein than gadobenate dimeglumine in PVP.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Vernuccio F, Cannella R, Gozzo C, et al. Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine? Abdom Radiol (NY). 2020. PMID: 32435849. doi:10.1007/s00261-020-02578-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。